CTpostprocedure | Â | Â | Â |
 | Early malignant progressors (n = 12) | Nonprogressors (n = 46) | P-value |
CTbaseline to malignant progression, hr | 10.8 ± 7.4 |  |  |
Δ time (CTPostprocedure-CTbaseline), hr | 3.9 ± 1.2 | 4.2 ± 3.2 | 0.716 |
ONSD (mm) | 5.92 ± 0.56 | 5.81 ± 0.71 | 0.599 |
ONSD/ETD ratio, % | 26.24 ± 1.99 | 25.45 ± 2.9 | 0.382 |
Δ ONSD/ETD ratio, % | 3.70 ± 2.78 | 1.89 ± 3.37 | 0.093 |
MLS (mm) | 6.08 ± 4.82 | 1.69 ± 2.21 | 0.009 |
Hemorrhagic pattern |  |  | < 0.001 |
No hemorrhage | 0 (0.0%) | 14 (30.4%) | Â |
HI 1 | 0 (0.0%) | 10 (21.7%) | Â |
HI 2 | 1 (8.3%) | 12 (26.1%) | Â |
PH 1 | 4 (33.3%) | 4 (8.7%) | Â |
PH 2 | 7 (58.3%) | 6 (13.0%) | Â |
CTD1 | Â | Â | Â |
 | Late malignant progressors (n = 7) | Nonprogressors (n = 39) | P-value |
CTbaseline to malignant progression, hr | 52.6 ± 51.5 |  |  |
Δ time (CTD1-CTbaseline), hr | 20.0 ± 11.3 | 27.4 ± 11.9 | 0.136 |
ONSD (mm) | 6.10 ± 0.36 | 5.67 ± 0.74 | 0.138 |
ONSD/ETD ratio, % | 26.93 ± 2.64 | 24.83 ± 2.94 | 0.085 |
Δ ONSD/ETD ratio, % | 3.60 ± 2.67% | 1.05 ± 2.69 | 0.025 |
MLS (mm) | 6.55 ± 2.87 | 3.64 ± 3.68 | 0.054 |
Hemorrhagic pattern | Â | Â | 0.819 |
No hemorrhage | 3 (42.9%) | 22 (56.4%) | Â |
HI 1 | 1 (14.3%) | 7 (17.9%) | Â |
HI 2 | 1 (14.3%) | 4 (10.3%) | Â |
PH 1 | 2 (28.6%) | 6 (15.4%) | Â |
PH 2 | 0 (0.0%) | 0 (0.0%) | Â |